Schrödinger Reports First Quarter 2024 Financial Results
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger to Announce First Quarter 2024 Financial Results on May 1
Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results
Schrödinger to Participate in Upcoming Investor Conferences
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger to Announce Fourth Quarter and Full-Year 2023 Financial Results
Schrödinger takes a step forward with AlphaFold in drug R&D